New pancreatic cancer drug daraxonrasib shows promising results in clinical trials
A new pharmaceutical treatment for pancreatic cancer, known as daraxonrasib or rasonque, has demonstrated significant efficacy in recent clinical trials. The drug, which targets the KRAS gene mutation present in over 90% of pancreatic tumors, is taken as a daily pill in combination with chemotherapy. In a small-scale study involving 61 patients with metastatic cancer, the treatment successfully rendered tumors undetectable in one out of every 12 participants. Experts describe these findings as highly encouraging, though they emphasize that larger-scale clinical trials are necessary before the drug can be approved for widespread use in public healthcare systems.
The medication received its initial approval from the United States Food and Drug Administration (FDA) on August 26, 2026. Following this, Greece has become one of the first countries outside the United States to secure access to the treatment. Eleftheria Tokatlidi, CEO of the Institute of Pharmaceutical Research and Technology (IFET), confirmed that the first supply of the drug arrived in Greece on November 6, 2026. Since October, over 110 patients have submitted requests for the medication, and treatment for eligible individuals has already commenced.